Rejoinder to “A hybrid phase I‐II/III clinical trial design allowing dose reoptimization in phase III” (Q5214492)
From MaRDI portal
scientific article; zbMATH DE number 7165180
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Rejoinder to “A hybrid phase I‐II/III clinical trial design allowing dose reoptimization in phase III” |
scientific article; zbMATH DE number 7165180 |
Statements
Rejoinder to “A hybrid phase I‐II/III clinical trial design allowing dose reoptimization in phase III” (English)
0 references
7 February 2020
0 references
clinical trial design
0 references
